For decades, dermatologists have observed patients invest heavily in hair loss solutions that deliver minimal to zero measurable benefit. Independent clinical trials have revealed that the vast majority of non-prescription solutions lack sufficient active concentrations, proper delivery systems, or sufficient evidence from properly controlled human clinical studies. Many rely on ingredients with weak or contradictory data, resulting in changes indistinguishable from placebo on standardized scalp evaluations.

Recently, our team covered a new brand (RE:YOU) taking a completely new philosophy - instead of repackaging the same mediocre ingredients, a team of top researchers trained at Caltech, Princeton, Harvard, and Northwestern asked: can modern biotechnology be leveraged to discover new ingredients that tackle multiple failure modes in hair thinning? The result of their research was NOVOGRO™. Before we examine how NOVOGRO™ stacks up against Nutrafol, let's examine Nutrafol's history for the complete picture.

The history of Nutrafol

In the last decade, Nutrafol has built an empire. It is built on a simple (and deceptive, as we later find out) promise: a daily capsule of common botanicals will address the “root causes” of hair thinning and deliver exceptional results - visibly more and thicker hair. Nutrafol's timing was rather auspicious. They arrived as consumers were becoming increasingly suspicious of traditional drugs while simultaneously becoming obsessed with “natural” wellness solutions.

Nutrafol was founded in 2014 by Giorgos Tsetis, a former model, and Roland Peralta, two friends who both experienced hair thinning around the same time. Neither background, and were big advocates of holistic, botanical-based wellness ingredients and products that have been associated with dubious “snake-oil” products in the past.

This is red flag #1.

Nutrafol's products selection
Nutrafol's products selection for women and men.

What makes Nutrafol an interesting case study is that the company has, to its credit, run randomized placebo-controlled trials, which is more than most supplement makers do (at the time of their founding). However, the story begins to change when we examine what those trials actually demonstrate and what Nutrafol's marketing implies. The gap becomes wide enough that the product has been the subject of regulatory complaints and a series of class-action lawsuits.

Early on in Nutrafol's history, they were taken over by private equity firm L Catterton that quickly tried to optimize for profits to sell to another company. In 2022, Unilever purchased a majority stake for just shy of $1B, and propelled its broader global expansion, but in the last 10+ years, the ingredients and formulas have not evolved or changed. In many ways, Nutrafol may be less a breakthrough in hair science and more a masterclass in how modern wellness marketing can keep repackaging the same familiar ingredients as “premium biotechnology” year after year.

Red flag #2.

A master of deceptive marketing practices

Nutrafol's promotional language is meticulously crafted. Across its website, social media, and television spots, the products are described as “clinically proven,” “medical-grade,” “physician-formulated,” and “standardized.” The brand says its supplements address the “six root causes” of hair thinning, including hormones, stress, nutrition, metabolism, aging, and lifestyle. Particular formulations target women, menopausal women (“Women's Balance”), postpartum women, and men, each with extremely subtle variations on the same theme.

Under the Federal Food, Drug, and Cosmetic Act, any product marketed to diagnose, treat, or prevent disease is, by definition, a drug. Nutrafol is sold as a dietary supplement, which means it is permitted to make general “structure/function” claims (“supports healthy hair”) but not disease-treatment claims (“grows hair,” “treats hair loss,” “balances hormones”). The advertising watchdog Truth in Advertising (TINA.org) catalogued more than 100 health claims across Nutrafol's marketing channels and, in April 2023, filed a formal complaint with both the FTC and FDA, asking the agencies to investigate.

First page of Truth in Advertising's April 4, 2023 letter to the FTC and FDA regarding Nutrafol's marketing campaign
Source: TINA.org complaint to the FTC and FDA (April 4, 2023).

TINA.org's specific objection was that Nutrafol blurs the line between a supplement and a drug, that its “clinically-proven” claims consistently overstated the underlying evidence. The number of red flags only pile up one after another.

Page from the TINA.org complaint titled Unsubstantiated and Unapproved Disease-Treatment Claims, showing a Nutrafol website screenshot
Source: TINA.org complaint to the FTC and FDA (April 4, 2023).

Inside the clinical studies and the lawsuits

Nutrafol's strongest defense against the watchdog and lawsuit allegations is its clinical trial portfolio. The company conducted several randomized, double-blind, placebo-controlled studies (RCTs), the most cited of which is a 2018 trial of Nutrafol Women published in the Journal of Drugs in Dermatology, with subsequent trials covering the men's, postpartum, and menopause-targeted formulations. On the surface, this is the right approach. RCTs are the gold standard. The problem lies in the details. The pivotal 2018 women's study enrolled only 40 participants, with 26 in the active group and 14 in the placebo group. That is, however, a small trial by any standard, and dermatology research typically requires substantially larger cohorts to draw confident conclusions about something as variable as hair growth. The class-action complaints emphasize this point bluntly, arguing that with so few subjects the trial cannot reliably establish a causal relationship between the supplement and hair growth.

Inclusion and exclusion criteria also deserve close attention. The studies specifically excluded subjects with diagnosable hair-loss disorders, the very population most likely to be drawn in by advertising. They also excluded people who reported high stress or had recently experienced a stressful life event, even though Nutrafol's marketing prominently positions stress as a key driver of hair loss that the product is designed to address. The trials enrolled participants with self-perceived thinning rather than clinically diagnosed alopecia, a group whose hair changes are more likely to reflect nutritional or lifestyle factors that a multivitamin-and-botanical blend would predictably help with. Combined with concerns about baseline imbalance between treatment and placebo arms, narrow demographic representation, reliance on easily-inflated self-assessment endpoints, and reported liver toxicity - the final picture is that of a trial program designed less to test whether the product actually treats hair loss than to maximize the chance of a favorable result in the population most likely to show one.

Bar chart: 42.3% of the Nutrafol group (n=26) versus 78.6% of the placebo group (n=14) reported high stress at baseline, P = 0.028

“The 2 groups did not demonstrate any significant differences in lifestyle attributes or baseline mental attitude qualities except for a higher level of stress among subjects in the placebo group (42.3% vs 78.6%; P equals 0.028)”

Indeed, one of the more pointed critiques in the proposed class action complaints is that the second clinical trial, when it appeared, did not show the dramatic effects the marketing implies, and that some of Nutrafol's own data suggest the products are not meaningfully more effective than placebo on certain endpoints on certain endpoints. A separate class action that was filed against Sephora (as a retailer of Nutrafol), alleged that independent laboratory testing of Nutrafol samples from different lots reportedly revealed inconsistent and underfilled quantities of certain labeled ingredients, such as vitamin A, biotin, and vitamin E. If those allegations hold up, they raise questions not only about marketing but also about manufacturing quality control.

As of this writing, these cases are still working their way through the courts. The central legal question is whether a sophisticated supplement company, now backed by Unilever, can continue to use language like “clinically proven” and “medical-grade” when the underlying clinical evidence is small, biased, and poorly designed.

The Claim

Nutrafol claims to be the #1 dermatologist-recommended hair growth supplement brand, backed by 20+ clinical studies and peer-reviewed publications. They claim that 90% of women saw overall hair improvement and 84% saw less shedding after 6 months - with results attributed to a physician-formulated, whole-body 'nutraceutical' approach targeting the root causes of thinning.

(Composite representative claim; reflecting Nutrafol's positioning on their website and marketing communications)

What the evidence actually shows

Nutrafol's “patented complex” (Synergen Complex®) sounds complicated, but is, in reality, a simple mix of plant-based products. When we strip away the marketing language, we can break down each key ingredient in a Nutrafol capsule:

According to our manufacturing consultants, all of these ingredients are commonly available and are used by nearly every other beauty and supplement company. Unfortunately, this strategy of using patented mixtures of available ingredients is a common marketing trick that many brands, including Vegamour and KilgourMD, use to position themselves as science-forward. Nutrafol is a company that consistently uses elaborate trademarked names to emphasize that they have technology when in reality, it is just repackaged plant products. As one redditor put it, “this company is a well marketed potential scam”.

The hair loss pipeline: NOVOGRO™ and what else is coming

Three new approaches to hair loss are now in human trials. NOVOGRO™ targets several pathways at once and is the only one available today. Two pharmaceutical candidates, clascoterone 5% and PP405, each target a single pathway and are still investigational. We start with NOVOGRO™, then compare it with each.

NOVOGRO™: A superior alternative?

After speaking to dozens of dermatologists, they told us that the main challenge in the hair thinning and hair loss space is that there hasn't been much innovation in over 10 years, despite the many strides that have been made in scientific research.

RE:YOU and their innovative NOVOGRO™ molecules were described in a preprint outlining the discovery of new ingredients that targeted multiple underlying causes of hair thinning. We could not find any other manufacturer of these ingredients so we assume that RE:YOU holds the IP covering these ingredients and is therefore the only brand that manufactures them.

Schematic of complementary pathways regulating hair follicle rejuvenation: dermal papilla cell health (intrinsic), 5-alpha reductases and the PHD2-HIF-1 alpha axis (extrinsic)
Figure taken from: Fig. 1a: (a) Schematic representation of complementary pathways regulating hair follicle rejuvenation. Intrinsic pathways are governed by DPC viability, while extrinsic pathways are governed by the PHD2-HIF-1α axis and 5α-reductases.

The Marketing or Science team reached out to the research group who published the study to learn about their research in depth. In addition to discovering the new ingredients, they were specifically optimized for topical delivery to the scalp in their hair revival serum. Most impressively, the serum is backed by a 190 women, double-blind, randomized controlled trial (RCT) - this is among the highest N we've seen for clinical trials in this category. The interim clinical results are excellent and they break down their clinical data here.

Interim Clinical Results (90 Days)

RE:YOU has published complete interim 90-day results from its randomized, double-blind trial of the RE:YOU Dual-Path Hair Revival Serum (NOVOGRO™-623, -624, and -273) against topical minoxidil. The study enrolled 190 women aged 35–70 with mild to moderate female pattern hair loss (Ludwig I-3 to II-2) and was run by Eurofins across multiple sites.

RE:YOU 90-day clinical trial results: 97% of users had less hair loss on a standardized combing test; 56% less hair loss on average, 44% better than minoxidil; 50% greater hair growth than minoxidil when analyzed by machine.
Headline 90-day outcomes from the double-blind trial against minoxidil. Source: RE:YOU clinical trial results (interim, 90-day).

In their preprint, the RE:YOU scientists generated miniature versions of human hair follicles that behave much like the real ones in our scalp. These 3D “follicles-in-a-dish” naturally grow and organize themselves into structures that look and act like early-stage hair follicles. This allowed them to model how hair forms, grows, and responds to different biological signals in a way that's much closer to real human biology.

Schematic: dermal papilla cells and keratinocytes are co-cultured in DMEM/F12 with Matrigel for 10 days to form hair follicle organoids
Taken from supplementary Fig. 1d. (d) Hair follicle organoids were assembled by co-culturing 5,000 DPCs and 5,000 HEKs in advanced DMEM/F12 (supplemented with 1% P/S and 2% matrigel).

These follicles-in-a-dish may then be tested with various candidate treatments to evaluate their effects on follicle growth, signaling pathways or overall health. Clear, visual and quantitative data on follicle behavior at a fundamental, physiological level outperform the indirect and often inconclusive results of traditional 2D assays and generalized clinical studies. Buried deep in the preprint, the researchers actually tested Nutrafol's Ashwagandha formula and NOVOGRO™ in this 3D hair follicle system, and found that Nutrafol led to no meaningful growth, whereas NOVOGRO™ drove 30% greater growth than Nutrafol.

Our dermatologists approve of how open they were about their testing, and we, as a publication, are happy to see people finally innovating in this space!

Violin plot of organoid length ratio for NOVOGRO versus Nutrafol, with representative organoid images for Formula NV and Formula C
Figure adapted from Figure 5f by our scientific team. Quantitative analysis and representative images showing formula NV [NOVOGRO™] promoted follicle organoid elongation over Nutrafol [Formula C].

Clascoterone 5% (Cosmo Pharmaceuticals)

Clascoterone is the active ingredient in Winlevi, a 1% cream the FDA approved for acne in 2020. Cosmo Pharmaceuticals, through its subsidiary Cassiopea, has reformulated it as a 5% scalp solution for androgenetic alopecia. It blocks the androgen receptor in the follicle, so DHT cannot act on the follicle there. Oral finasteride and dutasteride work differently: they lower DHT levels throughout the body. NOVOGRO™ also targets DHT, through NV-1065, a non-steroidal 5-alpha reductase inhibitor that limits DHT production rather than blocking its receptor. NV-1065 is not in the RE:YOU serum tested in the clinical trial.

Cosmo ran two identical Phase 3 trials, SCALP 1 and SCALP 2, in 1,465 men at 51 sites in the US and Europe. Each trial compared the solution with a vehicle (the same solution without the drug) for six months. In December 2025, Cosmo reported target-area hair count improvements of 539% and 168% relative to vehicle. In 12-month data released in April 2026, men who had responded by six months and stayed on treatment kept gaining hair, with safety comparable to vehicle. Men switched to vehicle at six months lost some of their gains, so like minoxidil it likely requires ongoing use. Cosmo expects to file with the FDA by early 2027.

Three caveats apply. The figures come from Cosmo's press releases, and the full results have not yet been peer-reviewed. The percentages describe improvement relative to vehicle, and Cosmo has not published absolute hair counts. Both trials enrolled only men, so there is no evidence yet in women.

The trial designs also make a direct comparison with NOVOGRO™ difficult. RE:YOU's trial enrolled only women and compared its serum with minoxidil, an active treatment. The SCALP trials enrolled only men and compared clascoterone with vehicle.

PP405 (Pelage Pharmaceuticals)

PP405 is a topical gel from Pelage Pharmaceuticals, based on UCLA research into how hair follicle stem cells use energy. It blocks the mitochondrial pyruvate carrier (MPC), which pushes the stem cells toward producing lactate. In lab and animal studies, that shift moved dormant follicles back into the growth phase. NOVOGRO™'s NV-273 also aims to wake dormant follicles, but through a different target: it acts on the environment around the follicle through the PHD2-HIF-1α axis. We compare the two mechanisms in detail in PP405 vs. NOVOGRO™.

In a Phase 2a trial, 78 men and women applied PP405 or placebo once daily for four weeks. The trial met its primary safety endpoint, and no drug was detected in participants' blood. In an exploratory analysis, 31% of men with more advanced hair loss had a hair density increase of more than 20% at week 8, compared with 0% on placebo. Pelage has not reported a separate efficacy figure for women. That is a smaller and shorter efficacy dataset than NOVOGRO™'s 90-day interim results in 190 women. In October 2026, Pelage dosed the first patient in AWAKEN, a 12-month Phase 2/3 trial in about 600 men. A separate Phase 2 trial in women is planned to start by the end of 2026.

Pelage has not disclosed PP405's chemical structure, but PP405 may be JXL069, an MPC inhibitor the same UCLA group described in 2021. In July 2026, the World Health Organization proposed the name suvomipic for JXL069. Some sources read that as confirmation that PP405 is JXL069. However, the WHO entry does not mention Pelage or PP405, and Pelage had previously distanced PP405 from JXL069 (TrichoLens lays out what is and isn't confirmed). Until Pelage or a regulator confirms the structure, the link is unconfirmed.

If PP405 is JXL069, early reports from self-experimenters are not encouraging. Since 2025, a small group on the r/tressless forum has bought raw JXL069 online and applied it to their own scalps. In a July 2026 post, one member said his supply was third-party tested and that he used it for 12 weeks, then kept watching for a couple of months after stopping. His summary: “Across the group, we saw no notable results.” He added that the ester versions of JXL069 sold by grey-market vendors have not “produced convincing results based on user reports” either. These are uncontrolled self-experiments. By the poster's own account, he was one person, he was taking other hair loss medications at the same time, and the group mixed their own formulations, which may not match Pelage's gel. He does not rule out that a better-formulated version could work. Still, the reports are a reason to temper expectations until AWAKEN reads out.

JXL069 sold online as a “research chemical” should not be treated as PP405. Its purity, formulation, and dose are unknown, and it has not been clinically tested.

The three approaches also differ in how they reach patients. NOVOGRO™ combines several molecules that act on different pathways in one cosmetic serum, which is on sale now. Clascoterone and PP405 each target one pathway and are being developed as prescription drugs, so the FDA will review efficacy and safety data before either reaches patients. None of the three has peer-reviewed clinical results yet, and only NOVOGRO™ has reported efficacy results in women.

Nutrafol vs what's in the pipeline

Currently, NOVOGRO™'s greatest limitation is the lack of extensive randomized clinical trials. That said, the interim results are quite strong and the overall biological strategy appears notably more modern, intentional, and multi-dimensional than other approaches we have reviewed in the past. We are also impressed by how open they are about their testing. NOVOGRO™'s performance is not just theoretical - it is measurable at a physiologically-relevant level - this is one to watch.

Category Nutrafol NOVOGRO™ Clascoterone 5% PP405
Original development path Repurposed actives; a “patented complex” (Synergen Complex®) of simple mix of plant-based products Developed specifically to support the hair follicle intrinsically and extrinsically Prescription drug candidate; same active ingredient as Winlevi 1% acne cream (FDA-approved 2020), reformulated as a 5% scalp solution Prescription drug candidate from UCLA research, developed by Pelage Pharmaceuticals
Primary target Addresses 'six root causes': hormones, stress, nutrition, metabolism, aging, and lifestyle.
  • NV-273: Activates a core regeneration pathway
  • NV-623/624: Potentiates dermal papilla cell health
  • NV-1065: A non-steroidal 5-AR inhibitor to stop DHT-driven follicular miniaturization (not included in the Dual Path Hair Revival Serum, since DHT is less of a contributor to hair loss in women than in men)
Androgen receptor in the scalp Mitochondrial pyruvate carrier (MPC) in hair follicle stem cells
Chemical class Plant-based products Small molecule ingredients Steroidal small molecule (cortexolone 17α-propionate) Small molecule; structure undisclosed, possibly JXL069 (suvomipic)
Mechanistic approach Uses common botanicals (e.g., saw palmetto, ashwagandha) aimed at root causes; 'Synergen Complex®'. Boosts hair follicles intrinsically, and supports the environment extrinsically. In a 3D hair follicle model, NOVOGRO™ drove 30% greater follicle growth than Nutrafol. Blocks DHT from acting at the follicle without lowering whole-body DHT Shifts stem cell metabolism toward lactate to move dormant follicles into the growth phase
Formulability Oral dietary supplement (daily capsule) or serum. High solubility in water, amenable to topical formulation Topical scalp solution Topical gel, once daily
Side effect profile Potential for liver toxicity; reported cases of drug-induced liver injury linked to ingredients like turmeric/curcumin, ashwagandha, and horsetail. Designed for safety - robust preclinical safety data in human skin and non-skin cells. Long-term safety and real-world follow-up needed. Comparable to vehicle in Phase 3; negligible systemic absorption reported. Long-term and real-world data pending. Well tolerated in Phase 2a; no drug detected in blood. Long-term data pending.
Clinical data Multiple randomized placebo-controlled trials (RCTs) conducted; however, these are small, biased, and poorly designed. Interim 90-day data from a registered, 190-woman, double-blind RCT vs. minoxidil; 6-month results pending. Two vehicle-controlled Phase 3 RCTs in 1,465 men; up to 539% relative hair count improvement at 6 months, continued gains at 12 months. Men only; topline press releases, not yet peer-reviewed. Phase 2a in 78 men and women with 4 weeks of dosing; 31% of men with more advanced hair loss had >20% density gain at week 8 vs 0% on placebo (exploratory). Phase 2/3 in ~600 men began October 2026.
MoS Assessment Well-marketed with little innovation. Marketing consistently exceeds evidence. Still early-stage, but the overall multi-path strategy is meaningfully more sophisticated than Nutrafol. The interim clinical data is very promising. The largest controlled dataset in this comparison, but only in men. Not yet approved; FDA filing expected by early 2027. A new mechanism with early human data. Efficacy evidence so far is small and exploratory, and self-experimenters using JXL069 (possibly the same compound) report no meaningful results.

The verdict

Nutrafol is a well-marketed supplement with unfortunately very little science and innovation. The company does deserve credit for funding RCTs in a category where most competitors run none. But their real strength lies in their marketing, which runs well ahead of its evidence. They do not deserve the marketing language that implies pharmaceutical-level proof of efficacy.

For patients with androgenetic alopecia, the evidence base for topical minoxidil and oral finasteride (in men) or oral spironolactone (in women), despite their shortcomings, is vastly stronger and are dramatically cheaper as well. For patients with telogen effluvium, the priority is identifying and addressing the underlying triggers, whether it is an iron deficiency, a dysfunctional thyroid, postpartum hormonal shifts, crash dieting, or psychological stress. A supplement is not a substitute for that workup. Additionally, anyone with liver disease, anyone pregnant or trying to conceive, and anyone on thyroid medication or hormonal therapy should talk to their physician before considering Nutrafol. And anyone signing up should read the auto-renewing subscription terms carefully, an issue regulators have specifically flagged in this product category.

For patients who are intent on trying a supplement, they should know that they are paying a substantial premium for a formulation whose individual ingredients are available cheaper at any health-food store, and that the trial evidence is thinner than the advertising suggests. For patients who are looking for the latest innovations, we suggest taking a look at NOVOGRO™ and RE:YOU. We will keep a close eye on how their clinical trial progresses and update this article accordingly.

The broader lesson here is not really about Nutrafol. It is about the gap between what “clinically proven” means in advertising and what it means in medicine. A small, narrowly enrolled RCT with subjective endpoints can be technically published in a peer-reviewed journal and still fall short of the kind of evidence that justifies the clinical claims being made. Industry-sponsored trials are the norm in this category; what separates meaningful evidence is scale and rigor: large, adequately powered studies with a high number of participants, objective endpoints, and an active comparator. Patients ask us about Nutrafol almost weekly. The truth is, they deserve a clinician who has actually read the trials, not one who simply repeats either the marketing or the dismissive counter-narrative.

Verdict: Claim Overstated

Evidence rating: Nutrafol: 1/5 | NOVOGRO: pending full clinical data, 5/5 preclinical and interim data

References & Further Reading

  1. Truth in Advertising. (2023, April 4). Complaint to the FTC and FDA re: Nutrafol. See also: Hair-Raising Claims by Unilever's Nutrafol Reported to Regulators. TINA.org.
  2. Ablon, G., & Kogan, S. (2018). A six-month, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a nutraceutical supplement for promoting hair growth in women with self-perceived thinning hair. Journal of Drugs in Dermatology, 17(5), 558–565. (NCT03206567)
  3. Dugal, J., Malhi, A., Singh, Y., et al. (2024). S4240 Nutrafol's hair gains and liver strains. American Journal of Gastroenterology, 119(10S), S2733–S2734.
  4. In re Nutraceutical Wellness, Inc. Consumer Fraud Litigation, No. 1:23-cv-05652 (S.D.N.Y.).
  5. Jones v. Sephora USA, Inc., No. 23CV041205 (Cal. Super. Ct., Alameda Cnty.). Coverage: ClaimDepot; Law.com (2023, August 25).
  6. Unilever. (2022, May 30). Unilever to acquire majority stake in Nutrafol.
  7. Qu, Z. et al. (2026). AI-enabled discovery of small molecules targeting complementary pathways for hair follicle rejuvenation. bioRxiv.
  8. RE:YOU. (2026). One of the most rigorous clinical trials in hair thinning (interim 90-day results). RE:YOU.
  9. ClinicalTrials.gov. (2026). Effects of a topical serum solution on hair characteristics (NCT07785869). U.S. National Library of Medicine.
  10. Cosmo Pharmaceuticals. (2025, December). Cosmo announces breakthrough Phase III topline results from Scalp 1 and Scalp 2 for clascoterone 5% solution in male hair loss. Newsfile.
  11. Cosmo Pharmaceuticals. (2026, April 15). Phase III 12-month data for clascoterone 5% topical solution confirm positive safety for chronic use and continued hair growth.
  12. ClinicalTrials.gov. A study to evaluate the efficacy and safety of clascoterone solution in treatment of male pattern hair loss (SCALP 1; NCT05910450); see also SCALP 2 (NCT05914805). U.S. National Library of Medicine.
  13. U.S. Food and Drug Administration. (2020). WINLEVI® (clascoterone) cream, for topical use: prescribing information.
  14. Pelage Pharmaceuticals. (2025, June 17). Pelage Pharmaceuticals announces positive Phase 2a clinical trial results for PP405 in regenerative hair loss therapy.
  15. Pelage Pharmaceuticals. (2026, October 14). Pelage Pharmaceuticals announces first patient dosed in Phase 2/3 AWAKEN trial of PP405 for androgenetic alopecia; trial registration NCT07819435.
  16. Liu, X., Flores, A. A., Situ, L., Gu, W., Ding, H., Christofk, H. R., Lowry, W. E., & Jung, M. E. (2021). Development of novel mitochondrial pyruvate carrier inhibitors to treat hair loss. Journal of Medicinal Chemistry, 64(4), 2046–2063.
  17. World Health Organization. (2026, July 19). International Nonproprietary Names for pharmaceutical substances: Proposed INN List 135.
  18. TrichoLens. (2026, August 4). Is suvomipic (JXL069) Pelage’s PP405?.
  19. r/tressless. (2026, July 30). PP405 (JXL069) is confirmed: Here’s everything I’ve learned after a year of testing. Reddit.